Nutrien's "Bargain" Is a Trap With a Cheap Price Tag

Let's get the obvious thing out of the way: Nutrien just reported a second quarter that should have been a non-event, and the market reacted like the building was on fire. Stock dropped 15.4% in a single day. That's not how you respond to a company that beat revenue, raised potash volume guidance, and handed shareholders $848 million in the first half of the year.

That disconnect is exactly where the real story lives.

Here's what actually happened on August 5. Nutrien posted $10.81 billion in revenue — a beat, and up roughly 4% year over year. Adjusted EBITDA came in at $2.43 billion, a 2% decline. But it was the bottom line that spooked people: adjusted EPS of $2.61 against a consensus of roughly $2.70. The miss wasn't some catastrophic collapse. It was driven by soft nitrogen volumes and elevated sulfur costs that hammered the phosphate segment, whose adjusted EBITDA cratered roughly 75% to a thin $23 million.

So the tape sold off 15%. Then, a few weeks later, it sold off again — this time on a headline. President Trump floated a potential U.S. potash supply deal with Belarus, and the entire sector—Nutrien, CF Industries, Mosaic—got hit with the same shovel. That's the thing that keeps me up at night about this name: you can do everything right operationally and still get wrecked by a single tweet about geopolitics.

Now, the bull case is genuinely not dumb. Nutrien is the world's largest potash producer, and the fundamentals around potash are improving, not deteriorating. Potash average net selling price rose 13% to $266 per ton. Nitrogen rose 14% to $416 per ton. Management raised full-year potash sales-volume guidance to 14.2–14.8 million tons, citing record first-half sales of 7.45 million tons and strong offshore demand. That's the second guidance lift of the year. Cost discipline is real: potash controllable cash costs held below $60 per tonne, mine automation hit 53%, and capex guidance was trimmed. Retail EBITDA rose 4%. The nitrogen market is tight heading into H2, with 85% of Q3 volumes already committed at summer pricing.

And the valuation looks soft. Forward P/E around 14.9x. A yield near 3%. Some models have the stock meaningfully overvalued, yes — GuruFocus put it nearly 29% over its GF Value — but that's a different argument about whether the stock is already too expensive, not about whether the business is broken.

Here's my problem with the "buy the dip" crowd, and I'll be blunt: they're conflating a cheap price with a cheap stock. Nutrien is trading in the low $70s, down from a high near $85, and the momentum story is ugly. Price is below its 20-day, 50-day, and 200-day moving averages. It failed to reclaim the $76–77 zone after the recent bounce. RSI is neutral-to-weak, not oversold. A near-term forecast band is pointing toward the low $60s. That's not a stock that's found a floor; that's a stock that's still falling with its engine running.

The other thing nobody wants to talk about: earnings quality. Revenue beats mean nothing if you can't translate higher prices into profit, and Nutrien has missed on EPS repeatedly because of sulfur, fuel, and mining taxes. A company that can't hold a profitable nitrogen business through a price up-cycle isn't exactly demonstrating a moat. And there's the Belarus overhang sitting right on top of everything — a U.S.–Belarus potash deal that could structurally depress the very pricing Nutrien is banking on.

So where does that leave us?

I'm not going to tell you to short a $30 billion fertilizer producer because a technical indicator looks bearish. The business is cash-generative, the balance sheet is strong, and if potash prices hold, this valuation has real upside. But "value trap" isn't a insult here — it's a description. Cheap cyclical stocks with a geopolitical sword over their head and a technical breakdown in progress are exactly the kind of thing that looks like a bargain and then keeps going lower.

My read: don't chase. The market already gave you a 15% discount on August 5 and then handed you another one on the Belarus headline. There's no urgency to buy the recovery the moment it bounces. If you believe in the multi-year potash story, be patient and let it come to you — a reclaim of $76–77 would tell you the downtrend is actually over, and a pullback toward the $63–68 zone would give you a far better price than anyone chasing today.

The real catalysts aren't happening now. Q3 earnings land November 4, and the Investor Day is November 30. That's over a month away. The market is pricing in a resolution that hasn't happened yet, on data that's six weeks old.

The lesson Nutrien is teaching is an old one and a painful one: a falling stock with a cheap multiple isn't a value play. It's a waiting game, and the patient get fed while the eager get filled.